Core Points - Salarius Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement, as of October 10, 2025, following prior compliance with Listing Rule 5550(a)(2) on September 9, 2025 [1][2] - The company is in the process of a planned merger with Decoy Therapeutics, which is expected to create multiple value-creating opportunities through Decoy's peptide conjugate therapeutics pipeline [3][5] - The combined company will be led by Decoy's co-founders and Salarius' acting CEO, indicating a strong leadership structure for the new entity [6] Compliance and Monitoring - Salarius is now fully compliant with all Nasdaq listing requirements, which is crucial for the merger with Decoy Therapeutics [2] - The company will be under a Mandatory Panel Monitor for one year starting October 10, 2025, to ensure ongoing compliance with the Equity Standard Requirement [4] Merger Details - The merger agreement with Decoy Therapeutics involves a business combination where Decoy will merge with a wholly owned subsidiary of Salarius, forming a new entity named Decoy Therapeutics [3] - Decoy's pipeline focuses on unmet medical needs in respiratory infectious diseases and GI oncology, with plans to advance a pan-coronavirus antiviral and other programs within the next 12 months [7] Product Development - The combined company aims to enhance Decoy's IMP3ACT platform for rapid design and manufacturing of peptide conjugate therapeutics, while also incorporating Salarius' SP-3164 into a targeted drug candidate [5] - Salarius' lead candidate, seclidemstat, is being studied for hematologic cancers, with ongoing clinical trials at MD Anderson Cancer Center [8][11]